Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) last traded at $9.79 with shares seeing a daily low of $9.26 and a high of $10.42. The change distinguishes the stock as one of the day’s most volatile.

Shares are trading at $9.79 quite a bit lower than the 50 day moving average of $10.93 and which is quite a bit below the 200 day moving average of $11.25. The 50 day moving average moved down $-1.14 and the 200 day average moved down $-1.46.

Short Interest

Traders are more bullish on Bellicum Pharmaceuticals, Inc. lately if you take note of the change in short interest. The firm experienced a fall in short interest from September 29, 2017 to October 13, 2017 of -9.02%. Short interest decreased from 5,145,936 to 4,681,676 over that timeframe. The short-interest ratio increased to 11.0 and the short interest percentage is 0.14% as of October 13.

Recent Analyst Ratings

August 9 investment analysts at Raymond James maintained a stock rating of “Outperform” and lowered the price target from $29.00 to $18.00. As of the latest earnings report the EPS was $-2.94 and is expected to be $-3.02 for the current year with 33,226,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.74 and the next full year EPS is anticipated to be $-2.95.

Company Information

Bellicum Pharmaceuticals, Inc., launched on July 14, 2004, is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Business’s product candidates include BPX-501, BPX-601 and BPX-701. The Business’s CID-based technologies include CaspaCIDe and GoCAR-T..